Other potential targets reported for managing these cardiovascular diseases include carnitine-palmitoyltransferase-1 (CPT-1), carnitine-palmitoyltransferase-2 (CPT-2), carnitine-acylcarnitine translocase, gamma-butyrobetaine hydroxylase, etc. These inactivated targets were found to change the process of fatty acid oxidation into glucose oxidation, which modified the overall cardiac workloads [75]. The gene discussed is CPT2; the disease is cardiovascular disorder.